eli lilly clinical trials tirzepatide New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Tirzepatide Obesity Drug Reduces Body

Types of GLP-1 agonists GLP-1 agonists are either short- or long-acting medications, depending on how long their effects last

Both hormones present with a U-shaped curve that shows us that too high or too low levels create a negative effect

However, recruitment challenges highlight potential barriers to scaling similar interventions, particularly in populations with varying degrees of health or cognitive impairment

These results hold in telehealth and in-person settings

Probucol, a lipid-lowering agent, also exhibits antioxidant properties that reduce intracellular oxidative stress and maintain normal cellular redox state by upregulating Nrf2 and GPX4 protein expression, thereby enhancing cardiomyocyte antioxidant capacity

I couldnt recommend something better